Moreover, according to the latest promoter competition mechanism, the PVT1 promoter, as a “non-standard” tumor suppressor, is a novel candidate for designing a new therapeutic strategy for tumors in which MYC serves as a carcinoma driver. Here, MYC is linked to neoplasm.